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Background: Long-term clinical outcomes after femoropopliteal (FP) stenting with nitinol stents have not yet been clear.
We investigated the mid-term efficacy of FP stenting with nitinol stents.
Methods: This study was a multicenter retrospective study. From April 2004 to December 2008, 511 consecutive patients
(639 limbs; mean age 71  7 years; 71% male) who underwent successful FP stenting with nitinol stents for de novo
lesions were retrospectively selected and analyzed in this multicenter study. All patients had a minimum follow-up of 6
months. Restenosis was defined as>2.4 of peak systolic velocity ratio by duplex or>50% stenosis by angiogram. Primary
patency was defined as treated vessels without restenosis and repeat revascularization. Secondary patency was defined as
target vessels that become totally occluded and are reopened by repeat revascularization.
Results: Sixty-one percent of the patients haddiabetes, 76%were claudicant, and20%were onhemodialysis.Mean lesion length
was 15175mm.Mean follow-upperiodwas 2211months. Primary patencywas 79.8%, 66.7%, and63.1%, and secondary
patency was 90.4%, 87.3%, and 86.2% at 1, 3, and 5 years, respectively. During the follow-up period, 53 patients (10%) died.
Of them, cardiovascular death was 38% and stent fracture had occurred in 14%. Onmultivariate analysis by Cox proportional
hazard ratio, cilostazol administration (hazard ratio [HR], 0.52;P< .0001), stent fracture (HR, 1.6; P .03), hemodialysis
(HR, 1.7; P  .01), and Trans Atlantic Inter-Society Consensus (TASC) II class C/D (HR, 2.4; P < .0001) were the
independent predictors of primary patency after successful FP stenting.
Conclusion: Clinical efficacy of nitinol stent implantation for FP disease was favorable for up to 5 years. ( J Vasc Surg
2010;52:608-15.)Endovascular therapy (EVT) for symptomatic lower ex-
tremity ischemia has becomewidespread due to technological
advances, and the strategy of revascularization has shifted
from surgical treatment toward EVT.1-3 EVT for femoropop-
liteal (FP) lesions remains unsatisfactory in terms of vessel
patency after the procedure,4-7 but the 2-year vessel patency in
the FP artery may be improved through use of a nitinol
stent8-10 in combination with pharmacotherapy,11,12 com-
pared to conventional endovascular treatment before the use
of nitinol stents. EVT with a nitinol stent for FP lesions is
widely performed, but long-term patency beyond 2 years is
still to be achieved.13 However, there are few reports on the
predictors of primary patency in the era of the nitinol stent.
Therefore, the purpose of this study was to examine the
midterm efficacy of nitinol stent implantation for FP disease
and to determine the factors associated with vessel patency
after treatment.
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608METHODS
Research design. Between January 2004 and Decem-
ber 2008, 1382 consecutive patients (1899 limbs) under-
went successful EVT for FP artery disease (from the super-
ficial femoral artery to the above-knee popliteal artery) at
each hospital involved in the study. Of these cases, 871
patients (1260 limbs) were excluded because of treatment
with angioplasty alone, restenotic lesions, use of a metallic
stent, Rutherford class 2, history of lower extremities
bypass surgery or EVT, or a follow-up interval6 months.
Therefore, 511 patients (639 limbs) who underwent suc-
cessful EVT with a nitinol stent for de novo lesions were
identified retrospectively and included in the analysis.
Baseline clinical characteristics and procedural data
were collected from hospital medical records or data-
bases. Clinical evaluation was performed at baseline and
at least every 6 months thereafter. The mean follow-up
period was 22  11 months (range, 6-64 months). The
clinical follow-up rate was 72% (n  366) at 1 year, 31%
(n  160) at 2 years, 15% (n  77) at 3 years, 6% (n 
33) at 4 years, and 1.4% (n  7) at 5 years. The study
protocol was approved by the hospital ethics commit-
tees, and the study was performed in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from every patient.
This study (Retrospective multicenter Analysis for
Femoropopliteal stenting Registry) is registered with the
University HospitalMedical InformationNetwork-Clinical
Trials Registry, as accepted by the International Committee
of Medical Journal Editors (No. UMIN000002726).
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cated with dual antiplatelet therapy (Aspirin 100mg/day
clopidogrel 75 mg/day or ticlopidine 200 mg/day) from
more than 2 days before the procedure. After insertion of a
6F or 7F sheath, an intra-arterial bolus of 3000 to 5000 IU
of heparin was injected and supplemented as required to
maintain an active clotting time of200 seconds. A 0.035-
inch, 0.018-inch, or 0.014-inch guidewire was used to
cross the lesion. In treating all stenoses and occlusions of
less than 10 cm in lesion length, the guidewire was ad-
vanced through the true lumen whenever possible. In
occlusions of 10 cm or more, the guidewire was crossed
subintimally. After passing the wire, balloon angioplasty
was performed. All lesions were dilated with an optimally
sized balloon. If a suboptimal result caused by flow-limiting
dissection or residual stenosis of 50% was found after
dilatation, a stent was implanted. For long total occlusion,
the entire lesion was covered by the stent in all cases. Two
types of nitinol stents were used: Luminexx (Bard, Murray
Hill, NJ) and S.M.A.R.T. (Cordis J&J, Miami, Fla). The
stent type was determined by the operators, and the stent
size was chosen to be 1 to 2 mm larger than the reference
vessel diameter. After the procedure, all patients were pre-
scribed lifelong aspirin (100 mg/day) and prolonged (at
least 1 month) clopidogrel 75 mg/day or ticlopidine 200
mg/day was recommended. Patients who had taken
cilostazol (200 mg/day) before the procedure continued
to receive cilostazol after the procedure. The resting ankle-
brachial index (ABI), Rutherford class, stent fracture, and
duplex ultrasound scan of the stented vessel were moni-
tored within 30 days and every 6 months thereafter in
concert with clinical examinations. Repeated revasculariza-
tion was performed based on clinical symptoms and find-
ings on duplex sonography or angiography scan.
Study outcome measures. The primary outcome
measure was primary patency after treatment, and the sec-
ondary outcome measures were secondary patency, free-
dom from all-cause mortality, and incidence of stent frac-
Table I. Patient characteristics
Patient characteristics
No. of patients 511
Age (y) 72.0  7.3
Male gender (%) 361 (71)
Body mass index 22.3  2.3
Hypertension (%) 451 (88)
Hyperlipidemia (%) 194 (38)
Diabetes (%) 313 (61)
Current smoker (%) 126 (47)
Hemodialysis (%) 100 (20)
CVD (%) 145 (28)
CAD (%) 284 (56)
IC/CLI (%) 388 (76)/123 (24)
Cilostazol (%) 319 (62)
Rutherford classification
II/III/IV/V/VI 133/255/42/68/13
CAD, Coronary artery disease; CLI, critical limb ischemia; CVD, cerebro-
vascular disease; IC, intermittent claudication.ture or leg amputation.Definitions. Restenosis was defined as 2.4 of peak
systolic velocity ratio by duplex scan14 or50% stenosis by
angiography. Undetectable signal in stented segments by
duplex scan was graded as complete occlusion. Primary pa-
tencywas defined as a treated vesselwithout restenosis and any
repeat revascularization. Secondary patency was defined as a
target vessel that subsequently became totally occluded and
was reopened by repeat revascularization. The total lesion
length referred to was the portion that was treated with
stenting. Stent fracture was defined as clear interruption of
stent struts identified by x-ray film from more than 2 projec-
tions, with resulting kink or misalignment along the axial
length of the stent. Leg amputation was defined as amputa-
tion above the ankle. Coronary artery disease (CAD) was
defined as stable angina with documented CAD, history of
percutaneous coronary intervention, history of coronary ar-
tery bypass graft surgery, or previous myocardial infarction.
Cerebrovascular disease was defined as a hospital or neurolo-
gist report with the diagnosis of transient ischemic attack or
ischemic stroke. Below-the-knee runoff was assessed by an-
giography before or after the procedure.
Statistical analysis. Values are reported as mean 
SD. Continuous variables were examined by use of the
unpaired t-test. Categorical variables were compared by 2
test. Survival curves were estimated by the Kaplan-Meier
method and compared with the log-rank test. Cox multi-
variate regression analysis was used to determine predictors
for primary patency. Clinically prespecified predictors (age,
male gender, diabetes, hypertension, hyperlipidemia, cur-
rent smoker, stroke, CAD, hemodialysis, runoff score,15
Table II. Lesion characteristics*
Lesion characteristics
Number of limbs 639
Approach
Antegrade (%)/retrograde (%) 486 (76)/153 (24)
Lesion length (mm) 150.5  75.1
Reference vessel diameter (mm) 5.2  0.5
Chronic total occlusion (%) 317 (50)
Calcified lesion (%) 217 (34)
Preprocedure ABI 0.57  0.15
Postprocedure ABI 0.84  0.15
Below-the-knee runoff
0/1/2/3 45/163/217/214
Runoff scores 5.6  2.3
IC/CLI 5.0  2.1/7.6  2.4
Type of nitinol stent
Luminexx (%) 135 (21)
S.M.A.R.T. (%) 504 (79)
Number of stent
Per lesion/per patients 1.8  0.8/2.3  1.1
Stent fracture (%) 88 (13.8)
TASC II classification
A/B/C/D 206/143/139/151
ABI, Ankle brachial index; CLI, critical limb ischemia; IC, intermittent
claudication.
*Calcified lesion defined as obvious densities noted within the apparent
vascular wall in the angiogram.Trans Atlantic Inter-Society Consensus [TASC] II C/D,
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vessel diameter, calcified lesion, use of a Luminexx stent,
cilostazol administration and stent fracture) with P  .05
on Cox univariate models were entered into the multivari-
able Cox regression model. A P value of  .05 was consid-
ered statistically significant.
RESULTS
Patient and lesion characteristics. The age of the
511 patients (639 limbs) ranged from 40 to 94 years(mean,
72.0  7.3 years). The characteristics of the patients and
lesions are shown in Tables I and II. The percentages of
patients with intermittent claudication (IC), resting pain,
and ischemic tissue loss were 75.9%, 8.2%, and 15.9%,
respectively. The mean lesion length was 150.5  75.1
mm. In the TASC II classification, 206 patients (32.2%),
143 patients (22.4%), 139 patients (21.8%), and 151 pa-
tients (23.6%) were in classes A, B, C, and D, respectively.
The mean runoff score in patients with IC was significantly
lower than that of patients with CLI (5.0  2.1 vs 7.6 
2.4; P .001). The ABI values preprocedure and postpro-
cedure were 0.57  0.15 and 0.84  0.15, respectively.
Outcome measures. In a treated limb-based analysis,
the overall primary patencies were 79.8%, 66.7%, and 63.1%,
and the secondary patencies were 90.4%, 87.3%, and 86.2% at
1, 3, and 5 years, respectively (Fig 1). In-stent restenosis was
found in 152 of 639 treated limbs (23.8%) during the obser-
vation period. Of these limbs, 2 were treated with lower
extremity bypass grafting, 11with continuedmonitoring, and
139with balloon angioplasty alone. After balloon angioplasty,
years 0 1
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Fig 1. Overall primary and secondary patency in 639
nitinol stent.re-restenosis occurred in 40.3% (56 of 139 limbs). Of the 56re-restenotic lesions, 13 were treated with lower extremity
bypass grafting, 5 with continued monitoring, and 38 with
repeat balloon angioplasty.
Significant differences in primary and secondary patencies
were found among the TASC II classifications (P .0001 by
log-rank test), although primary patency did not differ be-
tween TASC II classes A and B or between classes C and D
(Figs 2 and3).However, the primary patency amongTASCII
classes A/B or C/D differed significantly in patients with IC
or CLI (P  .0001 by log-rank test; Fig 4). Stent fracture
occurred in 13.8% of limbs (88 of 639). Most of these frac-
tures were single or multiple line fractures16 (73.9%; 65 of
88). The changes of ABI and Rutherford class are shown in
Fig 5. The improvements in ABI and Rutherford class were
maintained up to 5 years. Leg amputation was performed in
15 limbs (2.9%; 2 limbs that originally presented with claudi-
cation and 13 limbs with CLI). The limb salvage rates were
98.7%, 96.7%, and 96.7% at 1, 3, and 5 years, respectively (Fig
6), and these rates at 2 yearswere significantly lower in patients
withCLI than in thosewith IC (84.4%vs 99.5%;P .0001by
log-rank test).
Multivariate analysis performed using a Cox hazards
model showed that TASC II C/D (hazard ratio [HR],
2.39; 95% confidence interval [CI], 1.68-3.40; P .0001),
hemodialysis (HR, 1.65; 95% CI, 1.11-2.45; P  .013),
stent fracture (HR, 1.57; 95% CI, 1.06-2.34; P  .025),
and cilostazol administration (HR, 0.52; 95% CI, 0.37-
0.71; P  .0001) were independent predictors of primary
patency (Table III), and that TASC II C/D (HR, 5.76;
95% CI, 3.07-10.8; P  .0001) and cilostazol administra-
2 3 4 5
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Fig 2. Primary patency among TASC II classifications.
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with a successful procedure. The reference vessel diameter
(HR, 1.12; 95% CI, 0.86-1.47; P  .40) and runoff score
(HR, 1.03; 95% CI, 0.97-1.10; P  .30) were not predic-
tors of patency, and the type of stent used also had no
years 0 1
at risk
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Fig 4. Primary patency among TASC II class A/B or C/
intermittent claudication.
Fig 5. The changes of resting anckle-brachial index and
claudication.influence on patency.Freedom from all-cause mortality occurred in 94.8% of
cases at 1 year, 83.2% at 3 years, and 77.3% at 5 years (Fig 7).
During the observation period, 53 patients died. Cardiac
death occurred in 14 patients (26.4%) and cardiovascular
death (including cardiac death, stroke, and renal failure) ac-
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JOURNAL OF VASCULAR SURGERY
Volume 52, Number 3 Soga et al 613tients with CLI was significantly higher than in those with IC
(26.0% vs 5.4%; P  .0001), and death caused by infectious
disease, especially sepsis, was more frequent in patients with
CLI (21.9% vs 0%; P .02; Table IV).
DISCUSSION
In this study, provisional stenting was performed as a
bailout measure in patients with a suboptimal outcome.
Primary stenting for FP disease remains controversial,17 but
provisional stenting is acceptable due to its improvement of
acute results. However, in-stent restenosis after the procedure
is a major limitation. Of the 139 restenotic lesions in which
balloon angioplasty was performed, re-restenosis occurred in
56 (40.3%) and this high incidence of re-restenosis is of
concern. However, recent studies in a relatively limited num-
ber of cases have shown good outcomes using a paclitaxel-
coated balloon18,19 and the patency is likely to improve in
future treatment of patients with restenosis.
The primary patency in patients with IC at 5 years after
years 0 1
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Fig 6. Limb salvage rate. CLI, Critical
Table III. Multivariate analysis of primary patency
Variables HR 95% CI P value
TASC II class C/D 2.39 1.68-3.40 .0001
Hemodialysis 1.65 1.11-2.45 .013
Stent fracture 1.57 1.06-2.34 .025
Cilostazol administration 0.52 0.37-0.71 .0001
CI, Confidence interval; HR, hazard ratio; TASC, Trans-Atlantic Inter-
Society Concensus.FP bypass grafting has been reported to be 77.2% for anabove-knee vein graft and 57.4% for an above-knee poly-
tetrafluoroethylene graft.19 In this study, the primary pa-
tency of 5 years after FP stenting was 75.9% for patients
with IC in the TASC II A/B group and 51.5% for those in
the TASC II C/D group (Fig 4). The outcome in the
TASC II A/B group but not that in the TASC II C/D
group, was similar to that for above-knee FP bypass grafting
with a vein graft. Similarly, the primary graft patency in
patients with CLI 5 years after bypass grafting has been
found to be 66% to 69% for an above-knee vein graft and
47% to 48% for an above-knee polytetrafluoroethylene
graft.20,21 In this study, the primary patency was 68.0% in the
TASC II A/B group and 42.4% (at 4 years) in the TASC II
C/D group (Fig 5). In patients with CLI caused by an FP
lesion who were classified as TASC II A/B, the outcomes
were good and close to those for above-knee FP bypass
graftingwith a vein graft.However, as for patientswith IC, the
outcomes for patients with CLI in the TASC II C/D group
were not comparable to those for above-knee FP bypass
grafting. However, despite the poorer outcome in the TASC
II C/D patients, EVTmay be an alternative to bypass surgery
for patients with IC or CLI without a good vein graft.
The secondary patency was relatively good in all the
TASC II groups (Fig 3). A lesion can be easily dilated by
balloon angioplasty even if restenosis is advanced, provided
that the lesion is not occluded. Noninvasive duplex sonog-
raphy scan is effective for early detection,22 which is also
likely to contribute to maintenance of vessel patency. Pa-
tients with chronic lower extremity ischemia often have
2 3 4 5
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C/D, based on the condition of regular follow-ups.
Diagnosis of CLI is associated with a poor prognosis of
life and limb. In this study of 150 limbs in 123 patients with
CLI, 13 limbs (11 patients) required amputation and 32
patients died in a mean follow-up period of 17  10
months. The bypass vs angioplasty in severe ischemia of the
leg (BASIL) study,23 a landmark trial of first-line treatment
for patients with CLI, showed that the rate of avoidance of
limb amputation/death in patients treated with balloon
angioplasty was similar to that in patients treated with
surgery. In this study, we treated patients with CLI with a
balloon-angioplasty–first strategy. In the BASIL trial, the
amputation/death-free survival rates in the balloon-angio-
plasty–first group were 71% and 52% at 1 and 3 years after
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Fig 7. Freedom from all-cause mortality in 511 pat
Table IV. Causes of death
Causes
Total
n  53/511
Cardiac death (%) 14 (26.4)
Stroke (%) 4 (7.5)
Renal failure (%) 2 (3.8)
Malignancy (%) 8 (15.1)
Sepsis (%) 7 (13.2)
Pneumonia (%) 8 (15.1)
Others (%) 8 (15.1)
Unknown (%) 2 (3.8)
CLI, Critical limb ischemia; IC, intermittent claudication.surgery, respectively, which are similar to our results of77.7% and 58.1% at the same respective times. Therefore,
our results confirm the poor prognosis of CLI and suggest
no differences in response to treatment between Japanese
and Western patients.
The efficacy of cilostazol after EVT for FP lesions has
been shown previously.11,12 In this study, the primary
patency in the cilostazol-treated group (407 limbs) was
significantly higher than that in the group that did not
receive cilostazol (232 limbs; 76.4% vs 62.8% at 2 years;
unadjusted P  .0003). There were some differences in
baseline data between the two groups, with the cilostazol
group including more patients with diabetes (67.2% vs
58.7%; P .03), more smokers (30.7% vs 20.7%; P .03),
and more patients treated with a S.M.A.R.T. stent (83.3%
vs 64.6%; P  .049). However, cilostazol was found to be
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(33.3) 7 (21.9) .35
(4.8) 3 (9.4) .53
(4.8) 1 (3.1) .76
(33.3) 1 (3.1) .003
(0) 7 (21.9) .021
(9.5) 6 (18.8) .36
(14.3) 5 (15.6) .89
(0) 2 (6.3) .24p Intn 
7
1
1
7
0
2
3
0an independent predictor of primary patency (Table III)
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systemic therapy after EVT.
The efficacy of the nitinol stent has been shown, but out-
comes within 2 years are evaluated in most studies. The lack of
data for 2 years ormore after FP stenting amongTASCII classes
makes it difficult to compare the patency with lower extremity
bypass grafting. Therefore, it is important to evaluate the clinical
efficacy of the self-expandable nitinol stent for FP lesions among
TASC II classes up to 5 years after stenting.
Study limitations. There are several limitations that
may have affected our clinical outcomes. First, this study
was a retrospective, nonrandomized analysis, despite being
a large-scale, multicenter study. Second, only two types of
nitinol stents were implanted because these were the only
available stents in Japan at the time. In addition, the low rate of
patients with CLI (24%) and stent fracture (13.8% at a mean
follow-up time of 22 months), and the high rate of cilostazol
administration (62%) may have contributed to the overall
patency. Therefore, further investigation of the new genera-
tion of nitinol stents is needed. Finally, clinical follow-up
angiography or duplex ultrasound scans were not performed
based on a strict protocol because of the retrospective enroll-
ment of patients. Despite these limitations, the findings in this
study indicate that good vessel patency is likely after FP
stenting with a self-expandable nitinol stent.
CONCLUSION
The clinical efficacy of self-expandable nitinol stent
implantation for FP disease was favorable for up to 5 years.
A TASC II C/D status, hemodialysis, stent fracture, and
cilostazol administration were independent predictors of
primary patency after FP stenting.
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